How to appeal an Aetna adult car-t cell therapy denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna adult car-t cell therapy denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for adult car-t cell therapy
Cited policy: Aetna Clinical Policy Bulletin — Ciltacabtagene Autoleucel (Carvykti)
FDA-approved indication: r/r multiple myeloma after >=1 prior line including IMiD + anti-CD38 mAb, lenalidomide-refractory (Apr 2024 2L+ expansion via CARTITUDE-4) OR after >=4 prior lines (Feb 2022). Age >=18. ECOG 0-1. Adequate organ + cardiac function (LVEF >=45%, CrCl >=40, no NYHA III/IV CHF). No prior BCMA-directed CAR-T. Administered at FACT-accredited REMS-certified ATC. Bridging therapy + Flu/Cy LD covered as part of episode.
How Aetna denies adult car-t cell therapy — and how to counter it
Where Aetna pushes back: 1) 'Must try second auto-HSCT first'; 2) Prior anti-BCMA ADC (belantamab) deemed exclusionary; 3) Bridging therapy line counted against PA; 4) Out-of-state ATC denial.
Counter-arguments that hold up: CARTITUDE-4 (San-Miguel NEJM 2023;389:335) — Carvykti vs SOC (DPd / PVd) in 2L+ lenalidomide-refractory MM with PFS HR 0.26 — basis for FDA Apr 5 2024 2L+ expansion + NCCN MM v3.2024 preferred 2L+ pathway. Salvage second auto-HSCT inferior to CAR-T per NCCN + IMWG. CARTITUDE-4 entry criteria allowed prior anti-BCMA ADC (belantamab); only prior BCMA CAR-T excluded. CMS NCD 110.24 covers FDA-approved indications. REMS-mandated ATC + SCA pathway for out-of-state per ACA network-adequacy.
What Aetna typically denies for adult car-t cell therapy
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Yescarta
- Kymriah
- Tecartus
- Breyanzi
- Carvykti
- Abecma
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna adult car-t cell therapy denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for adult car-t cell therapy?
For adult car-t cell therapy, Aetna most often denies on: 1) 'Must try second auto-HSCT first'; 2) Prior anti-BCMA ADC (belantamab) deemed exclusionary; 3) Bridging therapy line counted against PA; 4) Out-of-state ATC denial. The strongest counters: CARTITUDE-4 (San-Miguel NEJM 2023;389:335) — Carvykti vs SOC (DPd / PVd) in 2L+ lenalidomide-refractory MM with PFS HR 0.26 — basis for FDA Apr 5 2024 2L+ expansion + NCCN MM v3.2024 preferred 2L+ pathway. Salvage second auto-HSCT inferior to CAR-T per NCCN + IMWG. CARTITUDE-4 entry criteria allowed prior anti-BCMA ADC (belantamab); only prior BCMA CAR-T excluded. CMS NCD 110.24 covers FDA-approved indications. REMS-mandated ATC + SCA pathway for out-of-state per ACA network-adequacy.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Adult CAR-T cell therapy appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com